Pirfenidone inhibits early neointimal proliferation following arterial injury.
Waller
Julian R
JR
Division of Transplant Surgery, Royal College of Surgeons of England, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK. julian@waller79.fsnet.co.uk
Toomey
D
D
Metcalfe
M S
MS
Margolin
S B
SB
Nicholson
M L
ML
D000821:Animal Feed; D000818:Animals; D002455:Cell Division; D019587:Dietary Supplements; D006965:Hyperplasia; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology*; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology*; D014652:Vascular Diseases / Q000473:pathology / Q000517:prevention & control*
D011728:Pyridones; D014409:Tumor Necrosis Factor-alpha; C093844:pirfenidone